Acute coronary syndrome in the patient with diabetes: Is the management different?

Current Cardiology Reports

Volumn 12, Issue 4, 2010, Pages 321-329

  Amin, Amit P ^a   Marso, Steven P ^a  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

Acute coronary syndrome; Antiplatelet agents; Clopidogrel; Diabetes mellitus; Drug eluting stents; Percutaneous coronary intervention; Prasugrel; Revascularization

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADD ON THERAPY; ARTERY DISEASE; BARE METAL STENT; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; EARLY INTERVENTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; RECOMMENDED DRUG DOSE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; DIABETES MELLITUS; DRUG-ELUTING STENTS; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 77956394853     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0118-5     Document Type: Review

References (48)

1. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes. Diabetes Care 2004, 27:1047-1053.
2. Fox CS, Coady S, Sorlie PD, et al.: Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 2007, 115:1544-1550.
3. Marso SP, Safley DM, House JA, et al.: Suspected acute coronary syndrome patients with diabetes and normal troponin-I levels are at risk for early and late death: Identification of a new high-risk acute coronary syndrome population. Diabetes Care 2006, 29:1931-1932.
4. Donahoe SM, Stewart GC, McCabe CH, et al.: Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775. This study conclusively demonstrates the adverse prognosis in diabetic patients with ACS. In over 60,000 ACS patients, 10,613 (17%) of whom had diabetes pooled from 11 TIMI trials conducted from 1997 to 2006 demonstrated a nearly twofold risk of short-term (30 days) and long-term (1-year) mortality associated with diabetes, independent of all other risk factors. It is especially noteworthy that this increased risk persisted even after implementing both contemporary revascularization and pharmacologic treatment strategies and despite the best possible evidenced-based and protocol-mandated care delivered in randomized clinical trials.
5. Brogan GX, Peterson ED, Mulgund J, et al.: Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care 2006, 29:9-14.
6. Colwell JA, Nesto RW: The platelet in diabetes. Diabetes Care 2003, 26:2181-2188.
7. De Berardis G, Sacco M, Strippoli GF, et al.: Aspirin for primary prevention of cardiovascular events in people with diabetes: Metaanalysis of randomised controlled trials. BMJ 2009, 339:b4531.
8. Baigent C, Blackwell L, Collins R, et al.: Aspirin in the primary and secondary prevention of vascular disease: Collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
9. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR: Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials. JAMA 2009, 301:1909-1919.
10. American Diabetes Association: Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(Suppl 1):S13-S61.
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee [no authors listed]. Lancet 1996, 348:1329-1339.
12. Bhatt DL, Marso SP, Hirsch AT, et al.: Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002, 90:625-628.
13. Pinto DS, Kirtane AJ, Pride YB, et al.: Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol 2008, 101:303-307.
14. Colwell JA; American Diabetes Association: Aspirin therapy in diabetes. Diabetes Care 2004, 27(Suppl 1):S72-S73.
15. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
16. Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358:527-533.
17. Chen ZM, Jiang LX, Chen YP, et al.: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
18. Sabatine MS, Cannon CP, Gibson CM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189.
19. Sabatine MS, Cannon CP, Gibson CM, et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005, 294:1224-1232.
20. Ho PM, Peterson ED, Wang L, et al.: Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008, 299:532-539.
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006, 55:780-784.
22. Roffi M, Chew DP, Mukherjee D, et al.: Platelet glycoprotein IIb/ IIIa inhibitors reduce mortality in diabetic patients with non-STsegment- elevation acute coronary syndromes. Circulation 2001, 104:2767-2771.
23. Mehilli J, Kastrati A, Schuhlen H, et al.: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004, 110:3627-3635.
24. Kastrati A, Mehilli J, Neumann FJ, et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006, 295:1531-1538.
25. Anderson JL, Adams CD, Antman EM, et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1-e157.
26. Mahaffey KW, Cohen M, Garg J, et al.: High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: Outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005, 294:2594-2600.
27. Blazing MA, de Lemos JA, White HD, et al.: Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-STsegment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA 2004, 292:55-64.
28. Cola C, Brugaletta S, Martin Yuste V, et al.: Diabetes mellitus: A prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag 2009, 5:101-119.
29. Rao SV, Eikelboom JA, Granger CB, et al.: Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1193-1204.
30. Stone GW, McLaurin BT, Cox DA, et al.: Bivalirudin for patients with acute coronary syndromes. NEngl JMed 2006, 355:2203-2216.
31. Feit F, Manoukian SV, Ebrahimi R, et al.: Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: A report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2008, 51:1645-1652.
32. Stone GW, Witzenbichler B, Guagliumi G, et al.: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
33. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: Influence of aspirin resistance on platelet function profiles in patients on longterm aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006, 97:38-43.
34. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
35. Angiolillo DJ, Bernardo E, Ramirez C, et al.: Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006, 48:298-304.
36. Wiviott SD, Braunwald E, Angiolillo DJ, et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636. The TRITON-TIMI 38 trial was a landmark trial that showed a greater benefit of intense platelet inhibition with prasugrel in patients with diabetes (12.2% vs 17.0%; HR, 0.70; P<0.001) versus those without diabetes. Furthermore, prasugrel was even more effective among insulintreated diabetic patients than diabetic patients treated with oral agents. Despite this increased efficacy in diabetics, safety was not compromised. The rates of TIMI major bleeding were similar among subjects with diabetes for clopidogrel and prasugrel. Thus, these data support the robust benefit of prasugrel in diabetic patients in decreasing ischemic events and stent thrombosis without an excess in risk of bleeding and may be particularly valuable in treating the diabetic patient with ACS.
37. Goraya TY, Leibson CL, Palumbo PJ, et al.: Coronary atherosclerosis in diabetes mellitus: A population-based autopsy study. J Am Coll Cardiol 2002, 40:946-953.
38. Mak KH, Faxon DP: Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 2003, 24:1087-1103.
39. Moreno PR, Murcia AM, Palacios IF, et al.: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180-2184.
40. Abaci A, Oguzhan A, Kahraman S, et al.: Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999, 99:2239-2242.
41. Lindsey JB, House JA, Kennedy KF, Marso SP: Diabetes duration is associated with increased thin-cap fibroatheroma detected by intravascular ultrasound with virtual histology. Circ Cardiovasc Interv 2009, 2:543-548. This was an intravascular ultrasound study with virtual histology that demonstrated that diabetic patients have a higher frequency of vulnerable plaque classified as TCFA especially among persons with duration of diabetes greater than 10 years.
42. Wallentin L, Lagerqvist B, Husted S, et al.: Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000, 356:9-16.
43. Cannon CP, Weintraub WS, Demopoulos LA, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879-1887.
44. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group [no authors listed]. Lancet 1994, 343:311-322.
45. Grines C, Patel A, Zijlstra F, et al.: Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: Six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003, 145:47-57.
46. Brar SS, Leon MB, Stone GW, et al.: Use of drug-eluting stents in acute myocardial infarction: A systematic review and metaanalysis. J Am Coll Cardiol 2009, 53:1677-1689.
47. Stone GW, Lansky AJ, Pocock SJ, et al.: Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009, 360:1946-1959.
48. Morrison DA, Sethi G, Sacks J, et al.: Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: A multicenter, randomized trial. J Am Coll Cardiol 2001, 38:143-149.